Abstract | BACKGROUND: METHODS: This was a retrospective cohort study. Premature infants diagnosed with Candida infections from October 2003 to July 2004 were brought to the neonatal intensive care unit at the Center of Perinatal Medicine, Nara Medical University Hospital. Four newborns were given 0.5-1.0 mg/kg per day micafungin. RESULTS: Four premature infants (mean +/- SD gestational age, 24.1 +/- 0.9 weeks; mean +/- SD birthweight, 579.3 +/- 80.5 g) experienced complications from Candida infection; two cases of the fungal infection were caused by Candida glabrata and two cases were caused by Candida albicans. MCFG was administered at 0.5 or 1.0 mg/kg per day (mean dosage days, 9.8 +/- 3.1 days) and it decreased beta- D-glucan levels while improving clinical symptoms in all cases. Additionally, there were no apparent side-effects. CONCLUSION: MCFG is both effective and tolerable for use in premature infants suffering from Candida infections.
|
Authors | Chiharu Kawaguchi, Ikuyo Arai, Hajime Yasuhara, Reiko Sano, Toshiya Nishikubo, Yukihiro Takahashi |
Journal | Pediatrics international : official journal of the Japan Pediatric Society
(Pediatr Int)
Vol. 51
Issue 2
Pg. 220-4
(Apr 2009)
ISSN: 1442-200X [Electronic] Australia |
PMID | 19405920
(Publication Type: Journal Article)
|
Chemical References |
- Antifungal Agents
- Echinocandins
- Lipopeptides
- beta-Glucans
- Micafungin
|
Topics |
- Antifungal Agents
(therapeutic use)
- Candidiasis
(blood, drug therapy)
- Echinocandins
(therapeutic use)
- Female
- Humans
- Infant, Extremely Low Birth Weight
- Infant, Newborn
- Infant, Premature
- Infant, Premature, Diseases
(drug therapy)
- Lipopeptides
(therapeutic use)
- Male
- Micafungin
- Retrospective Studies
- Treatment Outcome
- beta-Glucans
(blood)
|